EP1689346A4 - Epha2 agonistic monoclonal antibodies and methods of use thereof - Google Patents

Epha2 agonistic monoclonal antibodies and methods of use thereof

Info

Publication number
EP1689346A4
EP1689346A4 EP04811773A EP04811773A EP1689346A4 EP 1689346 A4 EP1689346 A4 EP 1689346A4 EP 04811773 A EP04811773 A EP 04811773A EP 04811773 A EP04811773 A EP 04811773A EP 1689346 A4 EP1689346 A4 EP 1689346A4
Authority
EP
European Patent Office
Prior art keywords
methods
monoclonal antibodies
agonistic monoclonal
epha2 agonistic
epha2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04811773A
Other languages
German (de)
French (fr)
Other versions
EP1689346A2 (en
Inventor
Michael S Kinch
Kelly Carles-Kinch
Jane C Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Purdue Research Foundation
Original Assignee
MedImmune LLC
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC, Purdue Research Foundation filed Critical MedImmune LLC
Publication of EP1689346A2 publication Critical patent/EP1689346A2/en
Publication of EP1689346A4 publication Critical patent/EP1689346A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
EP04811773A 2003-11-20 2004-11-19 Epha2 agonistic monoclonal antibodies and methods of use thereof Withdrawn EP1689346A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52417703P 2003-11-20 2003-11-20
PCT/US2004/039112 WO2005051307A2 (en) 2003-11-20 2004-11-19 Epha2 agonistic monoclonal antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
EP1689346A2 EP1689346A2 (en) 2006-08-16
EP1689346A4 true EP1689346A4 (en) 2007-11-21

Family

ID=34632874

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04811773A Withdrawn EP1689346A4 (en) 2003-11-20 2004-11-19 Epha2 agonistic monoclonal antibodies and methods of use thereof

Country Status (7)

Country Link
EP (1) EP1689346A4 (en)
JP (1) JP4860477B2 (en)
KR (1) KR20060135671A (en)
CN (1) CN1905899B (en)
AU (1) AU2004293034B2 (en)
CA (1) CA2546763A1 (en)
WO (1) WO2005051307A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
JP2006501153A (en) 2002-05-23 2006-01-12 パーデュー・リサーチ・ファウンデーション Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004220459B2 (en) 2003-03-12 2010-08-05 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2005224081B2 (en) 2004-03-12 2011-06-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CN102746401A (en) 2004-03-12 2012-10-24 瓦斯基因治疗公司 Polypeptide compound for inhibiting angiogenesis and tumor growth
AU2005277567A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
US20060204512A1 (en) 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
JP2009521219A (en) * 2005-12-21 2009-06-04 メディミューン，エルエルシー Affinity optimized EphA2 agonist antibodies and methods of use thereof
JP2010530437A (en) * 2007-06-18 2010-09-09 メディミューン，エルエルシー Synergistic treatment of cells expressing EphA2 and ErbB2
CA2696164C (en) 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
PL2199390T3 (en) 2007-08-30 2017-06-30 Daiichi Sankyo Company, Limited Anti-epha2 antibody
JP5808349B2 (en) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー Biomarkers for theranosis
BR112012025593A2 (en) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings circulating biomarkers for disease
CN103168104B (en) * 2010-07-22 2016-09-28 加利福尼亚大学董事会 Antitumor-antigen antibody and using method thereof
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2016171242A1 (en) * 2015-04-24 2016-10-27 第一三共株式会社 Detection of epha2
CN115025217B (en) * 2022-05-13 2023-05-05 广东齐美医药生物科技集团有限公司 Use of stem cell lysate in combination with active polysaccharide and tyrosinase inhibitor in preparation of drugs or cosmetics

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
US20040091486A1 (en) * 2002-05-10 2004-05-13 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HU MIN ET AL: "Antibody targeting of the EphA2 receptor tyrosine kinase on breast cancer cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 1234, XP008079516, ISSN: 0197-016X *
HU MIN ET AL: "EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells.", MOLECULAR CANCER RESEARCH : MCR OCT 2004, vol. 2, no. 10, October 2004 (2004-10-01), pages 533 - 540, XP002435680, ISSN: 1541-7786 *
LANDEN CHARLES N JR ET AL: "Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer", JNCI CANCER SPECTRUM, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 98, no. 21, 1 November 2006 (2006-11-01), pages 1558 - 1570, XP002421774, ISSN: 1475-4029 *
MILLER KATHY D ET AL: "EA5, novel EphA2-targeted monoclonal antibody, inhibits growth and metastasis in human breast cancer xenografts.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, no. Suppl. S, April 2005 (2005-04-01), & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005, pages 132, XP002435681, ISSN: 0197-016X *

Also Published As

Publication number Publication date
CN1905899B (en) 2011-09-28
JP4860477B2 (en) 2012-01-25
AU2004293034B2 (en) 2012-02-02
WO2005051307A3 (en) 2006-09-08
EP1689346A2 (en) 2006-08-16
JP2008500021A (en) 2008-01-10
WO2005051307A2 (en) 2005-06-09
AU2004293034A1 (en) 2005-06-09
KR20060135671A (en) 2006-12-29
CN1905899A (en) 2007-01-31
CA2546763A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
EP1689346A4 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
HK1219487A1 (en) Cd20-specific antibodies and methods of employing same cd20
SG10201606980VA (en) Anti-cd3 antibodies and methods of use thereof
IL179102A (en) Humanized fcγriib specific antibodies and methods of use thereof
HK1208472A1 (en) Antibodies that bind cell-associated ca 125/o722p and methods of use thereof ca125/o772p
IL178593A (en) Fcγriib-specific antibodies and methods of use thereof
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
EP1614693A4 (en) Purification of human monoclonal antibody and human polyclonal antibody
IL172689A0 (en) Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
IL175935A0 (en) Solid forms of anti-egfr antibodies
EP1833849A4 (en) Fc gamma riib-specific antibodies and methods of use thereof
IL190502A0 (en) Anti-addl monoclonal antibody and use thereof
EP1717250A4 (en) Monoclonal antibody and use thereof
EP1633785A4 (en) Human monoclonal antibodies against bacillusanthracis protective antigen
IL205511A0 (en) Methods and compositions for the production of monoclonal antibodies
EP1812065A4 (en) High affinity antibodies against hmgb1 and methods of use thereof
IL174016A (en) Monoclonal antibodies to m-csf and uses thereof
SI1587542T1 (en) Use of anti-cd100 antibodies
HK1098825A1 (en) Human monoclonal antibodies against cd20
IL149701A0 (en) Use of anti-ctla-4 antibodies
EP1572077A4 (en) Uses of monoclonal antibody 8h9
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
IL182943A0 (en) Ovr110 antibody compositions and methods of use
AU2003220079A8 (en) Uses of monoclonal antibody 8h9
IL172533A0 (en) Humanized anti-ccr2 antibodies and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060620

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK YU

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101ALI20061031BHEP

Ipc: C07K 16/28 20060101ALI20061031BHEP

Ipc: C12P 21/08 20060101ALI20061031BHEP

Ipc: A61K 39/395 20060101AFI20061031BHEP

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/20 20060101ALI20071004BHEP

Ipc: C12N 15/63 20060101ALI20071004BHEP

Ipc: C12N 15/13 20060101ALI20071004BHEP

Ipc: A61P 35/00 20060101ALI20071004BHEP

Ipc: C07H 21/04 20060101ALI20071004BHEP

Ipc: C07K 16/28 20060101ALI20071004BHEP

Ipc: C12P 21/08 20060101ALI20071004BHEP

Ipc: A61K 39/395 20060101AFI20061031BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20071019

17Q First examination report despatched

Effective date: 20080619

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081230